Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ACT008
MIFTS: 54

Actinic Keratosis

Categories: Cancer diseases, Genetic diseases, Skin diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Actinic Keratosis

About this section

MalaCards integrated aliases for Actinic Keratosis:

Name: Actinic Keratosis 12 73 36 54 15 17 70 32
Senile Hyperkeratosis 12 29
Seborrheic Keratosis 70
Sk - Solar Keratosis 12
Actinic Keratosis 12
Keratosis, Actinic 44
Solar Keratosis 12

Classifications:

MalaCards categories:
Global: Cancer diseases Genetic diseases
Anatomical: Skin diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:8866
KEGG 36 H02429
ICD9CM 34 702.0
MeSH 44 D055623
NCIt 50 C3148
SNOMED-CT 67 267858008
ICD10 32 L57.0
UMLS 70 C0022602 C0022603
Sources

Summaries for Actinic Keratosis

About this section
KEGG : 36 Actinic keratosis (AK) is a common cutaneous lesion associated with chronic exposure to ultraviolet (UV) radiation. AK presents scaly, erythematous papule or plaque and is considered the earliest clinically recognizable manifestation of squamous cell carcinoma.

MalaCards based summary : Actinic Keratosis, also known as senile hyperkeratosis, is related to keratosis and in situ carcinoma. An important gene associated with Actinic Keratosis is TP63 (Tumor Protein P63), and among its related pathways/superpathways are GPCR Pathway and Cytokine Signaling in Immune system. The drugs Diclofenac and Prilocaine have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and liver, and related phenotypes are homeostasis/metabolism and growth/size/body region

Wikipedia : 73 Actinic keratosis (AK), sometimes called solar keratosis or senile keratosis, is a pre-cancerous area of... more...

Sources

Related Diseases for Actinic Keratosis

About this section

Diseases in the Actinic Keratosis family:

Keratosis, Familial Actinic

Diseases related to Actinic Keratosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 386)
# Related Disease Score Top Affiliating Genes
1 keratosis 33.0 TP53 HRAS FLG CDKN2A
2 in situ carcinoma 31.4 TP53 MYC HRAS CDKN2A
3 keratosis, seborrheic 31.2 TYR TP53 MC1R CDKN2A
4 squamous cell papilloma 31.2 TP53 HRAS CDKN2A
5 squamous cell carcinoma 31.1 TP63 TP53 PTGS2 MYC MMP9 MMP2
6 keratoacanthoma 31.0 TP53 MYC FLG
7 albinism 30.9 TYR MITF MC1R
8 anogenital venereal wart 30.9 TP53 TMC8 CDKN2A
9 lentigo maligna melanoma 30.9 MMP9 MMP2 MITF MC1R
10 skin disease 30.8 TYR TP63 TP53 MITF MC1R HRAS
11 basal cell carcinoma 30.7 TYR TP63 TP53 PTGS2 MMP9 MMP3
12 human papillomavirus infectious disease 30.6 TP53 FLG CDKN2A
13 bowenoid papulosis 30.5 PTGS2 FLG CDKN2A
14 rosacea 30.5 MMP9 MMP3 IRF4
15 skin squamous cell carcinoma 30.5 TP53 HRAS CDKN2A
16 merkel cell carcinoma 30.5 TP53 MYC KRT20 CDKN2A
17 lymphangioma 30.4 TP53 PTGS2 MYC HRAS
18 papilloma 30.3 TP63 TP53 PTGS2 PCNA KRT20 FLG
19 retinoblastoma 30.3 TP53 PCNA MYC CDKN2B CDKN2A
20 skin benign neoplasm 30.3 TYR TP63 KRT20 HRAS
21 vitiligo-associated multiple autoimmune disease susceptibility 1 30.3 TYR MITF MC1R
22 osteogenic sarcoma 30.2 TP53 MYC MMP9 MMP2 CDKN2A
23 skin carcinoma 30.2 TYR TP53 TMC8 SOX10 PTGS2 MYC
24 plasmacytoma 30.1 MYC IRF4 CDKN2A
25 esophageal cancer 30.1 TP53 PTGS2 MYC MMP9 MMP2 HRAS
26 oculocutaneous albinism 30.1 TYR MITF MC1R
27 melanoma 29.9 TYR TP53 SOX10 MYC MMP9 MMP2
28 myelodysplastic syndrome 29.8 TP53 MYC MMP9 HRAS FAS CDKN2B
29 renal cell carcinoma, nonpapillary 29.7 TP53 MMP9 MMP2 MITF KRT20 HRAS
30 rheumatoid arthritis 29.7 PTGS2 MMP9 MMP3 MMP2 FLG FAS
31 gastric cancer 29.2 TP53 PTGS2 PCNA MYC MMP9 MMP2
32 actinic cheilitis 11.2
33 bowen's disease 10.7
34 lentigines 10.6
35 inverted follicular keratosis 10.5
36 trachea carcinoma in situ 10.5 HRAS CDKN2A
37 extracranial arteriovenous malformation 10.5 MMP9 MMP2
38 vulvar intraepithelial neoplasia 10.5 TP53 CDKN2A
39 pancreatic signet ring cell adenocarcinoma 10.5 TP53 HRAS
40 focal myositis 10.5 MMP9 MMP2
41 esophagus verrucous carcinoma 10.5 TP53 CDKN2A
42 middle ear squamous cell carcinoma 10.5 MMP9 CDKN2A
43 ovarian seromucinous carcinoma 10.5 TP53 CDKN2A
44 acute transverse myelitis 10.5 MMP9 MMP2
45 spitz nevus 10.5 TP53 HRAS CDKN2A
46 adult malignant schwannoma 10.4 TP53 HRAS CDKN2A
47 malignant exocrine pancreas neoplasm 10.4 TP53 HRAS CDKN2A
48 carcinosarcoma 10.4 TP53 HRAS CDKN2A
49 nasal cavity cancer 10.4 TP53 HRAS CDKN2A
50 prostate squamous cell carcinoma 10.4 TP53 HRAS CDKN2A

Graphical network of the top 20 diseases related to Actinic Keratosis:



Diseases related to Actinic Keratosis
Sources

Symptoms & Phenotypes for Actinic Keratosis

About this section

MGI Mouse Phenotypes related to Actinic Keratosis:

46 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.46 CDKN2A CDKN2B FAS HRAS IRF4 MC1R
2 growth/size/body region MP:0005378 10.45 CDKN2A FAS HRAS IRF4 MC1R MITF
3 behavior/neurological MP:0005386 10.42 CDKN2A FAS HRAS IRF4 MC1R MITF
4 cellular MP:0005384 10.42 CDKN2A CDKN2B FAS IRF4 MC1R MITF
5 immune system MP:0005387 10.42 CDKN2A CDKN2B FAS IRF4 MC1R MITF
6 hematopoietic system MP:0005397 10.38 CDKN2A CDKN2B FAS IRF4 MC1R MITF
7 endocrine/exocrine gland MP:0005379 10.36 CDKN2A CDKN2B FAS HRAS MITF MYC
8 mortality/aging MP:0010768 10.36 CDKN2A CDKN2B FAS HRAS MITF MMP2
9 integument MP:0010771 10.35 CDKN2A CDKN2B FAS HRAS MC1R MITF
10 neoplasm MP:0002006 10.32 CDKN2A CDKN2B FAS HRAS IRF4 MC1R
11 craniofacial MP:0005382 10.25 FAS HRAS MC1R MITF MMP2 MYC
12 digestive/alimentary MP:0005381 10.24 CDKN2A FAS HRAS MMP9 MYC PTGS2
13 nervous system MP:0003631 10.23 CDKN2A FAS HRAS MITF MMP2 MMP3
14 no phenotypic analysis MP:0003012 10.21 CDKN2A CDKN2B HRAS MC1R MITF MYC
15 limbs/digits/tail MP:0005371 10.18 FAS MC1R MITF MMP9 MYC SOX10
16 muscle MP:0005369 10.15 CDKN2A FAS HRAS MMP2 MMP9 MYC
17 normal MP:0002873 10.1 FAS HRAS MITF MMP2 MYC PTGS2
18 reproductive system MP:0005389 10 CDKN2A CDKN2B FAS MITF MMP9 MYC
19 pigmentation MP:0001186 9.97 CDKN2A FAS MC1R MITF MYC SOX10
20 renal/urinary system MP:0005367 9.97 CDKN2B FAS HRAS MITF MMP9 PTGS2
21 respiratory system MP:0005388 9.81 CDKN2A FAS HRAS MMP2 MMP9 PTGS2
22 skeleton MP:0005390 9.73 CDKN2A FAS HRAS MITF MMP2 MMP3
23 vision/eye MP:0005391 9.28 CDKN2A FAS MITF MMP2 MMP9 PTGS2
Sources

Drugs & Therapeutics for Actinic Keratosis

About this section

Drugs for Actinic Keratosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 140)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
2
Prilocaine Approved Phase 4 721-50-6 4906
3
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
4
Mineral oil Approved, Vet_approved Phase 4 8042-47-5
5
Bacitracin Approved, Vet_approved Phase 4 1405-87-4 10909430 439542
6
Menthol Approved Phase 4 2216-51-5 16666
7
Hydrogen peroxide Approved, Vet_approved Phase 4 7722-84-1 784
8
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
9
Imiquimod Approved, Investigational Phase 4 99011-02-6 57469
10
Aminolevulinic acid Approved Phase 4 106-60-5 137
11
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
12
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 68-26-8, 11103-57-4 445354
13 Radiation-Protective Agents Phase 4
14 Analgesics, Non-Narcotic Phase 4
15 Analgesics Phase 4
16 Cyclooxygenase Inhibitors Phase 4
17 Antirheumatic Agents Phase 4
18 Anti-Inflammatory Agents Phase 4
19 Anti-Inflammatory Agents, Non-Steroidal Phase 4
20 Protective Agents Phase 4
21 Anti-Arrhythmia Agents Phase 4
22 Sodium Channel Blockers Phase 4
23 Diuretics, Potassium Sparing Phase 4
24 Anesthetics, Local Phase 4
25 retinol Phase 4
26 Retinol palmitate Phase 4
27 Anti-Infective Agents Phase 4
28 Anti-Infective Agents, Local Phase 4
29 Anti-Bacterial Agents Phase 4
30 Viscosupplements Phase 4
31 Pharmaceutical Solutions Phase 4
32 Immunologic Factors Phase 4
33 Adjuvants, Immunologic Phase 4
34 interferons Phase 4
35 Dermatologic Agents Phase 4
36 Methyl 5-aminolevulinate Phase 4
37 Emollients Phase 4
38
Dimethyl sulfoxide Approved, Vet_approved Phase 3 67-68-5 679
39
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
40
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
41
Selenious acid Approved, Investigational Phase 3 7783-00-8
42
Selenium Approved, Investigational, Vet_approved Phase 3 7782-49-2
43 Keratolytic Agents Phase 3
44
Ethylene Phase 3 74-85-1 6325
45 Salicylates Phase 3
46 Antifungal Agents Phase 3
47 Antioxidants Phase 3
48 Sodium Selenite Phase 3
49 Sunscreening Agents Phase 3
50 Anesthetics Phase 3

Interventional clinical trials:

(show top 50) (show all 300)
# Name Status NCT ID Phase Drugs
1 Topical Ingenol Mebutate Versus 5% 5-fluorouracil Versus 5% Imiquimod Versus Photodynamic Therapy in Treatment of Actinic Keratosis: a Multi-centre Randomized Efficacy and Cost-effectiveness Study Unknown status NCT02281682 Phase 4 Imiquimod;5-fluorouracil;Ingenol mebutate
2 A Double-blind, Randomized, Placebo-controlled, 2-way Crossover Study to Assess the Potential Effect of Topically Applied Imiquimod Cream on Atrial Ectopy in Patients With Actinic Keratosis Unknown status NCT01413763 Phase 4 Imiquimod cream 3.75%;Placebo cream
3 A Randomised Double-blind Parallel-group Study to Evaluate the Long-term Effects of Eryfotona AK-NMSC® Cream in the Treatment of Cancerization Field in Patients With Actinic Keratosis. Unknown status NCT01656226 Phase 4
4 An Investigator-Initiated Study to Assess the Safety and Efficacy of Imiquimod 3.75% Cream When Used After Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses (AK) on Dorsal Hands and Forearms Unknown status NCT01229319 Phase 4 Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm;Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm
5 Comparative Intraindividual Study, About the Efficacy and Safety of Treatment of Actinic Keratoses With Photodynamic Therapy Between Acid Methyl Aminolevulinate Cream and Aminolevulinic Gel Unknown status NCT02647151 Phase 4 METHYLAMINOLEVULINATE HYDROCHLORIDE;AMINOLEVULINIC ACID HYDROCHLORIDE
6 Comparison of the Efficacy and Tolerability of Solaraze for 3 vs. 6 Months in Patients With Mild to Moderate Actinic Keratosis Located at the Face and Head Completed NCT00204542 Phase 4 Diclofenac;Diclofenac
7 Open-Label Safety and Pharmacokinetic Study of AldaraTM (Imiquimod) Cream, 5% for One, Two, or Three Treatment Cycles to Surface Areas Greater Than 25 cm2 With Actinic Keratosis Completed NCT00116649 Phase 4 imiquimod cream
8 A Comparison of the Efficacy of Ablative Fractional Laser-assisted Photodynamic Therapy According to the Density of Ablative Laser Channel in the Treatment of Actinic Keratosis Completed NCT03731988 Phase 4 lidocaine/prilocaine (5%) application;MAL application
9 Long-term Effects of Aldara® 5% Cream and Solaraze® 3% Gel in the Treatment of Actinic Keratoses on the Face or Scalp With Respect to the Risk of Progression to In-situ and Invasive Squamous Cell Carcinoma Completed NCT01453179 Phase 4 Imiquimod;Diclofenac
10 Long-term Effects of Aldara® 5% Cream and Solaraze® 3% Gel in the Treatment of Actinic Keratoses on the Face or Scalp (LEIDA) Completed NCT00777127 Phase 4 Imiquimod;Diclofenac
11 Photodynamic Therapy of Actinic Keratosis of the Face and Scalp With and Without Prior Curettage Completed NCT03697590 Phase 4 No curettage;Curettage
12 Vehicle-Controlled, Double-Blind Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Upper Extremities Completed NCT00115154 Phase 4 Aldara (imiquimod) cream, 5%
13 Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of Actinic Keratosis on the Face in Solid Organ Transplant Recipients Completed NCT02866695 Phase 4 ingenol mebutate gel 0.015%
14 Subject Reported Outcomes on Satisfaction, Safety and Efficacy With Luxerm® in the Field-directed Treatment of Thin or Non-hyperkeratotic and Non-pigmented Actinic Keratosis of the Face or the Scalp Completed NCT03511326 Phase 4 Methyl Aminolaevulinate 16% Cream
15 A Multi-center, OPen, InvEstigator Initiated Phase IV Clinical TRial to Evaluate the Efficacy and SaFety of Ingenol Mebutate Gel 0.015% on Face and Scalp & 0.05% on Trunk and Extremities in KorEan Patient With ACtinic KeraTosis (PERFECT) Completed NCT02716714 Phase 4 ingenol mebutate gel 0.015%;ingenol mebutate gel 0.05%
16 A Randomized Right/Left Clinical Trial to Evaluate the Use of Biafine Cream Versus Standard Care in Subjects With Actinic Keratosis Post Cryotherapy Completed NCT00695578 Phase 4 Biafine;Polysporin
17 Evaluating Skin Appearance Following 5-Flourouracil Cream for Treatment of Actinic Keratosis and the Effects of Topical Agents Completed NCT03279328 Phase 4 Topical Steroid Ointment;Skin Barrier Moisturier
18 Gene Expression in Renal Transplant Patients With Field Actinic Keratosis Undergoing Metvix® PDT Completed NCT01000636 Phase 4
19 A Pilot Prospective Clinical Trial to Evaluate the Efficacy and Safety of Large-Scale, Field-Directed Topical Therapy of Actinic Keratosis of the Chest With Ingenol Mebutate 0.015% Completed NCT02446223 Phase 4 Inggenol Mebutate 0.015%
20 A Randomized Study to Evaluate the Efficacy of Ingenol Mebutate on Actinic Keratoses and Field Cancerization Compared to Cryotherapy Completed NCT02990221 Phase 4 Ingenol mebutate
21 A Phase 4 Trial Comparing the Cumulative Incidence of SCC After Treatment With Ingenol Mebutate and Imiquimod for Multiple Actinic Keratoses on Face and Scalp. A Multi-centre, Randomised, Two-arm, Open Label, Active-controlled, Parallel Group, 36-month Trial Completed NCT01926496 Phase 4 Ingenol Mebutate Gel, 0.015%;Imiquimod Cream, 5%
22 A Randomised Double Blind, Placebo Controlled Study of the Efficacy of Topical Menthol for Pain Relief During Topical Photodynamic Therapy Completed NCT02984072 Phase 4 Menthol;Aqueous Cream
23 Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp Completed NCT02406014 Phase 4 Ingenol Mebutate Gel, 0.015%;Diclofenac sodium gel 3%
24 Measuring Adherence To Topical 5-Fluorouracil in a Clinic Population Completed NCT00696488 Phase 4 Fluorouracil 0.5%
25 UCI 14-92 / HS#2015-1889: Phase IV Study of Daylight Photodynamic Therapy With Aminolevulinic Acid for Actinic Keratoses Completed NCT03327831 Phase 4 Aminolevulinic Acid
26 Daylight Mediated Photodynamic Therapy for Actinic Keratoses: a Multicentre Study Comparing Two Photosensitizers (BF-200 ALA Versus MAL) Completed NCT02464709 Phase 4 Aminolevulinic Acid;Methyl 5-aminolevulinate
27 An Open-Label Study Assessing Subject Satisfaction With A-101 Hydrogen Peroxide Topical Solution, 40% (w/w) Treatment for Seborrheic Keratoses of the Face, Neck, and Decolletage Completed NCT03487588 Phase 4 A-101 Topical Solution
28 A Randomized, Parallel-Group, Vehicle-Controlled, Double-Blind Study of Topical Imiquimod 5% Cream Used as an Adjunct to Cryotherapy in the Management of Actinic Keratoses, With a Long-Term (1 Year) Follow-Up Completed NCT00110682 Phase 4 Imiquimod used as an adjunct to cryotherapy
29 An Open-Label 18-Month Safety Study of Fluorouracil Cream 0.5% for the Treatment of Actinic Keratoses Completed NCT00377273 Phase 4 fluorouracil cream 0.5%
30 Treatment of AKs With Daylight-PDT: Comparing Two Photosensitizers (BF-200 ALA and MAL) Completed NCT01893203 Phase 4 BF-200 ALA cream;MAL cream
31 Prospective, Randomized, Controlled, Multicenter, Two-armed, Study Comparing Daylight Photodynamic Therapy Using MAL With Cryosurgery for the Treatment and Prophylaxis of Actinic Keratoses in Photodamaged Skin of the Face Completed NCT02736760 Phase 4 Daylight photodynamic therapy using Methylaminolevulinate (MAL)
32 An Investigator-Initiated Study to Assess the Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses (AK) on Dorsal Hands Completed NCT02251652 Phase 4 Ingenol Mebutate
33 A Randomized, Evaluator-blinded, Bilateral Comparison of the Treatment of Facial Actinic Keratoses Using Combination Microneedling and Photodynamic Therapy With Aminolevulinic Acid and Blue Light Versus Photodynamic Therapy With Aminolevulinic Acid and Blue Light Using Two Different Incubation Times Completed NCT02622594 Phase 4 Aminolevulinic Acid (ALA)
34 Prospective, Controlled and Monocentric Study to Evaluate the Effects of Topical 3% Diclofenac in 2.5% Hyaluronic Acid Gel on Tumor Metabolism in the Treatment of Actinic Keratoses in Immunocompetent and Immunocompromised Patients Completed NCT01935531 Phase 4 3% diclofenac in 2.5% hyaluronic acid gel
35 A Randomized, Open-label, Assessor-blinded, Split-face Study of Imiquimod 5% Cream Applied After Cryotherapy of Actinic Keratoses Completed NCT00774787 Phase 4 imiquimod 5% cream
36 Aminolevulinic Acid-photodynamic Therapy for Facial Actinic Keratosis Treatment and Prevention: A Long-term (3 Years) Follow-up of Prospective, Randomized, Multicenter-clinical Trial Recruiting NCT03642535 Phase 4 ALA
37 A Study to Investigate the Effect of Different Durations of Ameluz Application on Response to Treatment of Acral Actinic Keratoses Recruiting NCT03963102 Phase 4 Ameluz
38 Clinical and Dermoscopic Evaluation of Long-pulsed 1064 nm Nd-YAG Laser Versus Trichloroacetic Acid 20% in Treatment of Keratosis Pilaris Recruiting NCT04797663 Phase 4 TCA 20%
39 An Exploratory, Open-label Study of Sequential Field-directed Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy Terminated NCT01203878 Phase 4 Photodynamic therapy;Imiquimod
40 Topical Imiquimod 5% Cream Therapy Versus Photodynamic Therapy With Methyl-aminolaevulinate 16% Cream of Actinic Keratoses in Organ Transplant Recipients Terminated NCT01538901 Phase 4 imiquimod 5% cream
41 Efficacy and Safety of Salkera Emollient Foam in the Treatment of Moderate to Severe Keratosis Pilaris, a Prospective Study Terminated NCT00944216 Phase 4 Salkera Emollient Foam
42 A RANDOMIZED, DOUBLE BLIND, MULTI-CENTER CLINICAL STUDY TO TEST THE SAFETY AND EFFICACY OF T4N5 LIPOSOME LOTION ON PATIENTS WITH XERODERMA PIGMENTOSUM IN THE PROTECTION AGAINST ACTINIC KERATOSES Unknown status NCT00002811 Phase 3 liposomal T4N5 lotion
43 Phase III Comparative Study About the Use of 5% 5-fluorouracil Cream Versus Its Utilization as Agent for Sequential Superficial Peeling in the Treatment of Advanced Photoaging Unknown status NCT01405144 Phase 3 5-fluoruracil
44 A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of the Safety and Effectiveness of A-101 Solution 40% in Subjects With Seborrheic Keratosis on the Trunk, Extremities and Face. Completed NCT02667236 Phase 3 A-101 Solution
45 A Randomized, Double-Blind, Vehicle-Controlled, PArallel Group Study of the Safety and Effectiveness of A-101 Solution 40% in Subjects With Seborrheic Keratosis on the Trunk, Extremities and Face. Completed NCT02667275 Phase 3 A-101 Solution
46 Safety and Efficacy of Photodynamic Therapy With Short Incubation Methylaminolevulinate Without Occlusion in the Treatment of Actinic Keratoses. Completed NCT00926952 Phase 3 Methylaminolevulinate (Metvix, Metvixia)
47 A Phase 3b Randomized, Double-blinded, Placebo-controlled, Multicenter, Efficacy and Safety Study of Imiquimod Cream Following Cryosurgery for the Treatment of Actinic Keratoses Completed NCT00894647 Phase 3 imiquimod cream;placebo cream
48 Phase 3 Study of Brand Generic and Placebo in Treatment of Actinic Keratosis Completed NCT01354717 Phase 3 Brand Carac;Generic 0.5% 5-fluorouracil cream
49 Evaluation of the Formulation of 5-aminolevulinic Acid With Dimethylsulfoxide in Photodynamic Therapy for Treatment of Actinic Keratosis Completed NCT01459393 Phase 3 5-ALA Photodynamic Therapy;Cryotherapy with liquid nitrogen
50 Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up Completed NCT02547363 Phase 3 LEO 43204 gel;Vehicle gel

Search NIH Clinical Center for Actinic Keratosis

Cochrane evidence based reviews: keratosis, actinic

Sources

Genetic Tests for Actinic Keratosis

About this section

Genetic tests related to Actinic Keratosis:

# Genetic test Affiliating Genes
1 Senile Hyperkeratosis 29
Sources

Anatomical Context for Actinic Keratosis

About this section

MalaCards organs/tissues related to Actinic Keratosis:

40
Skin, Eye, Liver, T Cells, Endothelial, Cortex, Colon
Sources

Publications for Actinic Keratosis

About this section

Articles related to Actinic Keratosis:

(show top 50) (show all 2402)
# Title Authors PMID Year
1
[Expression of cell proliferation and apoptosis biomarkers in skin spinocellular carcinoma and actinic keratosis]. 61 54
20098848 2009
2
The expression of p63 and p53 in keratoacanthoma and intraepidermal and invasive neoplasms of the skin. 54 61
19577853 2009
3
The characteristics of human papillomavirus expression and cell proliferation in actinic keratosis and Bowen's disease of the skin. 61 54
16905862 2006
4
Noncalcemic actions of vitamin D receptor ligands. 61 54
15798098 2005
5
Expression profiles of p63, p53, survivin, and hTERT in skin tumors. 54 61
15268709 2004
6
Expression of p53, bcl-2 and growth hormone receptor in atrophic type of actinic keratosis. 61 54
14757281 2004
7
Human papillomavirus infection in actinic keratosis and bowen's disease: comparative study with expression of cell-cycle regulatory proteins p21(Waf1/Cip1), p53, PCNA, Ki-67, and Bcl-2 in positive and negative lesions. 54 61
14562284 2003
8
Expression of p53, bcl-2 and growth hormone receptor in actinic keratosis, hypertrophic type. 54 61
12756585 2003
9
Large cell acanthoma. 54 61
12581141 2003
10
Expression of cell-cycle proteins p53, p21 (WAF-1), PCNA and Ki-67 in benign, premalignant and malignant skin lesions with implicated HPV involvement. 54 61
10429981 1999
11
Expression of proliferating cell nuclear antigen (PCNA) and apoptosis related antigen (LeY) in epithelial skin tumors. 54 61
9557786 1998
12
Evaluation of proliferating cell nuclear antigen as a surrogate end point biomarker in actinic keratosis and adjacent, normal-appearing, and non-sun-exposed human skin samples. 61 54
9162299 1996
13
[Decision criteria and patient characteristics for patient-oriented treatment of field cancerization : Standardized algorithm for personalized treatment concepts]. 61
33263779 2021
14
Invasive and in situ lesions of squamous cell carcinoma are independent factors for postoperative surgical-site infection after outpatient skin tumors surgery: A retrospective study of 512 patients. 61
33560553 2021
15
Cyclic calcipotriene 0.005% foam and 1% 5-fluorouracil cream after cryotherapy in treatment of hyperkeratotic actinic keratosis: A retrospective study. 61
32652187 2021
16
Ten-Year Follow-up of Persons With Sun-Damaged Skin Associated With Subsequent Development of Cutaneous Squamous Cell Carcinoma. 61
33760003 2021
17
High ROS Production by Celecoxib and Enhanced Sensitivity for Death Ligand-Induced Apoptosis in Cutaneous SCC Cell Lines. 61
33807213 2021
18
MicroRNA-130a acts as a tumor suppressive miRNA in cutaneous squamous cell carcinoma and regulates the activity of the BMP/SMAD1 pathway by suppressing ACVR1. 61
33766507 2021
19
Loss of retinoic acid receptor-related receptor alpha (Rorα) promotes the progression of UV-induced cSCC. 61
33664254 2021
20
Tirbanibulin: First Approval. 61
33713299 2021
21
High-frequency ultrasound in the diagnosis of the spectrum of cutaneous squamous cell carcinoma: Noninvasively distinguishing actinic keratosis, Bowen's Disease, and invasive squamous cell carcinoma. 61
33751714 2021
22
Frequency of Procedural and Medical Treatments of Actinic Keratosis. 61
33757796 2021
23
Daylight photodynamic therapy for actinic keratosis: Is it affected by the British weather? 61
32964500 2021
24
Red light photodynamic therapy with BF-200 ALA showed superior efficacy in the treatment of actinic keratosis on the extremities, trunk and neck in a vehicle-controlled Phase III study. 61
33744350 2021
25
Patient-reported outcomes of topical therapies in actinic keratosis: A systematic review. 61
33527673 2021
26
Effects of Solanum undatum extract (SR-T100) on photocarcinogenesis and photoaging of actinic keratosis. 61
33458860 2021
27
Cold Atmospheric Plasma (CAP) for the Treatment of Actinic Keratosis and Skin Field Cancerization: Clinical and High-Frequency Ultrasound Evaluation. 61
33738749 2021
28
The diagnostic value of p63, p16, and p53 immunohistochemistry in distinguishing seborrheic keratosis, actinic keratosis, and Bowen's disease. 61
33497503 2021
29
Xeroderma pigmentosum in Yemen. 61
33538348 2021
30
Chemical peelings for the treatment of actinic keratosis: a systematic review and meta-analysis. 61
32745330 2021
31
Long-term improvement on photoaging after ALA photodynamic therapy for actinic keratosis: A retrospective study. 61
33429100 2021
32
Comparison of Grenz ray and photodynamic therapy for field treatment of actinic keratoses on the forearm: A case series. 61
33040339 2021
33
Ingenol Mebutate as Treatment of Squamous Cell Carcinoma In Situ: A Case Series. 61
33538561 2021
34
Cutaneous Squamous Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches. 61
33572373 2021
35
Cutaneous Spindle Cell Squamous Cell Carcinoma in Cats: Clinical, Histological, and Immunohistochemical Study. 61
33577428 2021
36
Immobilization strategies of photolyases: Challenges and perspectives for DNA repairing application. 61
33383556 2021
37
Increased PD-L1 Expression in Human Skin Acutely and Chronically Exposed to UV Irradiation. 61
33615483 2021
38
The dermoscopic inverse approach significantly improves the accuracy of human readers for lentigo maligna diagnosis. 61
32592885 2021
39
Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis. 61
33567191 2021
40
Dermatoscopic findings and dermatopathological correlates in clinical variants of actinic keratosis, Bowen's disease, keratoacanthoma, and squamous cell carcinoma. 61
33583118 2021
41
Photodynamic therapy for actinic keratosis in vegan and omnivore patients: the role of diet on skin healing. 61
31076007 2021
42
Chemoprevention of keratinocyte carcinoma and actinic keratosis in solid-organ transplant recipients: Systematic review and meta-analyses. 61
32387631 2021
43
Comparative study of imiquimod 3.75% vs. photodynamic therapy for actinic keratosis of the scalp. 61
33566432 2021
44
Online consensus conferences for the development and update of clinical practice guidelines: A survey among participants of the German S3 guideline on actinic keratosis and cutaneous squamous cell carcinoma. 61
33617083 2021
45
A Critical Appraisal of Evidence- and Consensus-Based Guidelines for Actinic Keratosis. 61
33617511 2021
46
Interventions for Actinic Keratosis in Nonscalp and Nonface Localizations: Results from a Systematic Review with Network Meta-Analysis. 61
32645365 2021
47
Treatment of Actinic Keratosis: Does Effectiveness Depend on the Location? 61
33504437 2021
48
Increasing Access to Specialized Dermatology Care: A Retrospective Study Investigating Clinical Operation and Impact of a University-Affiliated Free Clinic. 61
33175327 2021
49
[Photodynamic therapy-trends and new developments]. 61
33301063 2021
50
Penile and scrotal infundibular cysts in an adolescent treated with sorafenib. 61
33481286 2021
Sources

Variations for Actinic Keratosis

About this section
Sources

Expression for Actinic Keratosis

About this section
Search GEO for disease gene expression data for Actinic Keratosis.
Sources

Pathways for Actinic Keratosis

About this section

Pathways related to Actinic Keratosis according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Super pathways Score Top Affiliating Genes
1
GPCR Pathway 63
Show member pathways
 13.71 TP53 PTGS2 MYC MMP9 MMP3 MMP2
2
Cytokine Signaling in Immune system 65
Show member pathways
 13.35 TP53 PTGS2 MYC MMP9 MMP3 MMP2
3
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.2 TP53 PCNA MYC MMP9 MMP3 HRAS
4
Human cytomegalovirus infection 36
Show member pathways
 12.95 TP53 PTGS2 MYC HRAS FAS CDKN2A
5
Aldosterone synthesis and secretion 36
Show member pathways
 12.9 TYR MITF MC1R HRAS CDKN2B CDKN2A
6
Endometrial cancer 36
Show member pathways
 12.8 TP53 PCNA MYC MMP9 MMP3 HRAS
7
Gastric cancer 36
Show member pathways
 12.77 TP53 MYC HRAS CDKN2B CDKN2A
8
Apoptosis Modulation and Signaling 1
Show member pathways
 12.6 TP63 TP53 MYC IRF4 HRAS FAS
9
Mitotic G1-G1/S phases 65
Show member pathways
 12.57 TP53 PCNA MYC CDKN2B CDKN2A
10
Glioma 36
Show member pathways
 12.55 TP53 MMP9 MMP2 MITF HRAS CDKN2B
11
Development IGF-1 receptor signaling 23
Show member pathways
 12.39 TP53 PCNA MYC HRAS
12
DNA Damage Response 1
Show member pathways
 12.38 TP53 MYC FAS CDKN2A
13
Cell cycle 36 1
12.35 TP53 PCNA MYC CDKN2B CDKN2A
14
Human T-cell leukemia virus 1 infection 36
12.31 TP53 MYC HRAS CDKN2B CDKN2A
15
Viral carcinogenesis 36
12.3 TP53 HRAS CDKN2B CDKN2A
16
MicroRNAs in cancer 36
12.29 TP63 TP53 PTGS2 MYC MMP9 HRAS
17
Transcriptional misregulation in cancer 36
12.23 TP53 MYC MMP9 MMP3 MITF
18
Proteoglycans in cancer 36
12.16 TP53 MYC MMP9 MMP2 HRAS FAS
19
Colorectal Cancer Metastasis 63
12.14 TP53 PTGS2 MYC MMP9 MMP2
20
Cellular senescence (KEGG) 36
12.09 TP53 MYC HRAS CDKN2B CDKN2A
21
Pathways in cancer 36
12.05 TP53 PTGS2 MYC MMP9 MMP2 MITF
22
Spinal Cord Injury 1
12.01 TP53 PTGS2 MYC MMP9
23
DNA Damage Response (only ATM dependent) 1
11.98 TP53 MYC HRAS CDKN2A
24
Direct p53 effectors 1
11.98 TP63 TP53 PCNA MMP2 FAS
25
TNF signaling pathway 36
11.97 PTGS2 MMP9 MMP3 FAS
26
Glioblastoma Multiforme 63
11.96 TP53 MYC HRAS CDKN2A
27
Senescence and Autophagy in Cancer 1
11.93 TP53 PCNA HRAS CDKN2A
28
Small cell lung cancer 36
11.86 TP53 PTGS2 MYC CDKN2B
29
Retinoblastoma (RB) in Cancer 1
11.83 TP53 PCNA MYC
30
Angiogenesis (CST) 4
11.83 PTGS2 MMP9 MMP3 MMP2
31
Validated targets of C-MYC transcriptional activation 1
11.8 TP53 MYC MMP9
32
Regulation of Wnt-mediated beta catenin signaling and target gene transcription 1
11.76 MYC MMP9 MMP2 MITF
33
Platinum drug resistance 36
11.74 TP53 FAS CDKN2A
34
Central carbon metabolism in cancer 36
11.72 TP53 MYC HRAS
35
Mitophagy - animal 36
11.71 TP53 MITF HRAS
36
Pathways Affected in Adenoid Cystic Carcinoma 1
11.69 TP53 MYC HRAS
37
LPA receptor mediated events 1
11.68 MMP9 MMP2 HRAS
38
Cell adhesion_ECM remodeling 23
11.65 MMP9 MMP3 MMP2
39
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.64 PTGS2 MMP9 MMP3 MMP2
40
IL-2 Gene Expression in Activated and Quiescent T-Cells 63
Show member pathways
 11.62 MYC MMP9 MMP2 HRAS
41
Hepatitis C and Hepatocellular Carcinoma 1
11.57 TP53 PTGS2 MYC
42
Interleukin-4 and 13 signaling 65
11.56 TP53 PTGS2 MYC MMP9 MMP3 MMP2
43
Aryl Hydrocarbon Receptor 1
11.54 PTGS2 MYC HRAS
44
Integrated Cancer Pathway 1
11.51 TP53 MYC CDKN2B
45
Bladder cancer 36 1
11.5 TP53 MYC MMP9 MMP2 HRAS CDKN2A
46
Signal transduction_JNK pathway 23
11.49 TP53 HRAS FAS
47
DNA damage_ATM/ATR regulation of G1/S checkpoint 23
11.49 TP53 PCNA MYC
48
Photodynamic therapy-induced AP-1 survival signaling. 1
11.49 TP53 MMP2 FAS CDKN2A
49
Melanocyte Development and Pigmentation 63
11.45 SOX10 MITF MC1R
50
Signaling mediated by p38-alpha and p38-beta 1
11.37 TP53 PTGS2 MITF
Sources

GO Terms for Actinic Keratosis

About this section

Cellular components related to Actinic Keratosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.8 TYR TP63 TP53 SOX10 PTGS2 PCNA
2 chromatin GO:0000785 9.7 TP63 TP53 SOX10 PCNA MYC MITF
3 protein-containing complex GO:0032991 9.1 TP63 TP53 PTGS2 MYC MITF CDKN2A

Biological processes related to Actinic Keratosis according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription by RNA polymerase II GO:0000122 10.08 TP63 TP53 SOX10 PCNA MYC MITF
2 apoptotic process GO:0006915 10.04 TP63 TP53 KRT20 HRAS FAS CDKN2A
3 positive regulation of transcription, DNA-templated GO:0045893 10 TP63 TP53 SOX10 MYC MITF IRF4
4 negative regulation of cell proliferation GO:0008285 9.99 TP53 PTGS2 HRAS CDKN2B CDKN2A
5 positive regulation of gene expression GO:0010628 9.99 TP53 SOX10 MYC MITF HRAS CDKN2A
6 positive regulation of apoptotic process GO:0043065 9.96 TP53 PTGS2 MMP9 FAS CDKN2A
7 negative regulation of apoptotic process GO:0043066 9.95 TP53 SOX10 PTGS2 MYC MMP9 MITF
8 ephrin receptor signaling pathway GO:0048013 9.79 MMP9 MMP2 HRAS
9 Ras protein signal transduction GO:0007265 9.77 TP53 HRAS CDKN2A
10 cellular response to drug GO:0035690 9.76 TP53 SOX10 MYC
11 extracellular matrix disassembly GO:0022617 9.75 MMP9 MMP3 MMP2
12 collagen catabolic process GO:0030574 9.72 MMP9 MMP3 MMP2
13 embryo implantation GO:0007566 9.71 PTGS2 MMP9 MMP2
14 pigmentation GO:0043473 9.7 TYR MITF MC1R
15 cell aging GO:0007569 9.67 TP63 TP53 HRAS
16 cellular response to UV GO:0034644 9.67 TP53 PTGS2 PCNA MYC
17 cellular senescence GO:0090398 9.65 HRAS CDKN2B CDKN2A
18 positive regulation of transcription by RNA polymerase II GO:0045944 9.65 TP63 TP53 SOX10 MYC MITF MC1R
19 melanin biosynthetic process GO:0042438 9.62 TYR MC1R
20 response to amyloid-beta GO:1904645 9.61 MMP9 MMP3 MMP2
21 cell cycle arrest GO:0007050 9.55 TP53 MYC HRAS CDKN2B CDKN2A
22 regulation of neuroinflammatory response GO:0150077 9.5 PTGS2 MMP9 MMP3
23 cellular response to UV-A GO:0071492 9.43 MMP9 MMP3 MMP2
24 cytokine-mediated signaling pathway GO:0019221 9.17 TP53 PTGS2 MYC MMP9 MMP3 MMP2

Molecular functions related to Actinic Keratosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.26 TYR TP63 TP53 TMC8 SOX10 PTGS2
2 chromatin binding GO:0003682 9.8 TP63 TP53 SOX10 PCNA MITF
3 DNA-binding transcription factor activity GO:0003700 9.8 TP63 TP53 SOX10 MYC MITF IRF4
4 transcription regulatory region sequence-specific DNA binding GO:0000976 9.73 TP63 TP53 SOX10 IRF4
5 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 9.63 TP63 TP53 SOX10 MYC MITF IRF4
6 p53 binding GO:0002039 9.54 TP63 TP53 CDKN2A
7 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.48 CDKN2B CDKN2A
8 bacterial-type RNA polymerase transcriptional activator activity, sequence-specific DNA binding GO:0001216 9.46 TP53 SOX10
9 transcription factor binding GO:0008134 9.43 TP53 SOX10 PCNA MYC IRF4 CDKN2A
10 MDM2/MDM4 family protein binding GO:0097371 8.8 TP63 TP53 CDKN2A
Sources

Sources for Actinic Keratosis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....